The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In that year, ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a potent inhibitor of mutated-BRAF (V600E and V600K), were approved by the U.S. Food and Drug Administration (FDA). In 2013, d...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aurora Health Care
2014-01-01
|
| Series: | Journal of Patient-Centered Research and Reviews |
| Subjects: | |
| Online Access: | http://digitalrepository.aurorahealthcare.org/cgi/viewcontent.cgi?article=1007&context=jpcrr |